AVIR
What one share of Atea Pharmaceuticals holds
Pharmaceutical Preparations
We are a late-stage clinical biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal chemistry, biochemistry and virology to discover, develop and commercialize novel, orally administered antivirals to treat serious viral diseases.
Atea Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.10 |
|---|---|
| Cash and investments | $0.95 |
| Book value | $2.55 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$0.90 | $0.00 | −$0.79 | — | −$3.60 |
| 2019 | — | −$1.39 | $0.00 | −$1.27 | — | −$4.91 |
| 2020 | $2.25 | −$0.51 | $0.00 | $13.74 | — | — |
| 2021 | $3.98 | $1.37 | $0.00 | −$0.99 | — | $8.54 |
| 2022 | — | −$1.39 | $0.02 | −$1.48 | — | $7.69 |
| 2023 | — | −$1.63 | — | −$1.02 | — | $6.65 |
| 2024 | — | −$2.00 | — | −$1.61 | — | $5.20 |
| 2025 | — | −$1.94 | — | −$1.62 | — | $3.53 |